Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Epidermolysis bullosa acquisita

Other Names for this Disease
  • Acquired epidermolysis bullosa
  • EB acquisita
  • EBA
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Newline Maker

How might epidermolysis bullosa acquisita be treated?

Due to the rarity of epidermolysis bullosa acquisita (EBA), data regarding the benefits of treatment is lacking. Treatments that have been tried, include systemic steroids, either alone or along with azathioprine, methotrexate, and cyclophosphamide, as well as intravenous immunoglobulin, rituximab and immunoadsorption.[1] To learn more regarding your treatment options, please speak with a healthcare provider.

Last updated: 10/24/2011

  1. Gurcan HM, Ahmed AR . Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin. Pharmacother. 2011;12(8):1259-1268;

Clinical Trials & Research for this Disease

  • lists trials that are studying or have studied Epidermolysis bullosa acquisita. Click on the link to go to to read descriptions of these studies.
  • The National Center for Research Resources (NCRR) in cooperation with Northwestern University has completed a clinical trial entitled 'Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita' (study ID: 199/11928, NU-511; NLM Identifier NCT00004359). To view the study abstract click on the link above.

    To locate information resulting from the completed study, you can either e-mail or call the National Library of Medicine (NLM) Customer Service. Include the title of the study, the study ID number, and the NLM Identifier, and a librarian at NLM can assist you in searching the medical literature for published results on the completed clinical trial.

    National Library of Medicine Customer Service
    Toll-free: 888-346-3656